Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 29, 2024
Vaccine Stocks Surge: $NVAX, $MRK, $PFE, $JNJ, $MRNA Up in a Week

Vaccine Stocks Surge: $NVAX, $MRK, $PFE, $JNJ, $MRNA Up in a Week

Robots for this group tickers :
Day Trader, Popular Stocks: Price Action Trading Strategy (TA&FA) 
Swing Trader, Popular Stocks: Price Action Trading Strategy - Pro Version (TA&FA) 

In recent times, Covid-19 vaccine companies have been under the spotlight due to their crucial role in combating the global pandemic. Tracking the performance of these companies provides valuable insights into market trends, investor sentiments, and potential future trajectories.

Theme and Tickers:

The theme revolves around prominent Covid-19 vaccine companies that include Novavax (NVAX), Merck & Co (MRK), Pfizer (PFE), Johnson & Johnson (JNJ), and Moderna (MRNA). These companies have experienced a noteworthy +5.72% increase in performance over the past week, signaling an upward trend in their stock values.

Positive Outlook and Volume Indicator:

Currently, the stocks in this group exhibit a positive outlook supported by the Volume Indicator. Tickeron's optimistic forecast predicts a potential further increase of over 4.00% within the next month, with a probability of 69%. Over the last month, the ratio of advancing to declining volumes stood at 1.55 to 1, indicating a bullish sentiment in the market for these stocks.

MA50MA10 Indicator:

Three stocks within this group have confirmed the positive outlook based on the MA50MA10 indicator, demonstrating consistent trends and an average likelihood of 66% for sustained positive movement.

Market Capitalization:

The average market capitalization of these vaccine companies stands at 166.6 billion USD. The market caps range from 648.6 million USD for NVAX to a substantial 381.3 billion USD for JNJ, indicating a broad spectrum in valuation among these entities.

Notable Price Movements:

The average weekly price growth for these stocks was 5.72%, with MRNA experiencing the highest growth at 11.73% while PFE faced a decline of 2.36%. Over a month, the average price growth was 8.9%, reflecting a strong upward trend. However, the average quarterly price growth was negative at -8.11%.

Recent Price Fluctuations:

  • JNJ: Significant market cap fluctuations were observed, with notable drops and jumps in valuation over recent dates, showcasing volatility in its stock value.
  • MRNA: Witnessed impressive weekly gains but experienced a downturn in the past, hinting at a possible reversal in the trend.
  • PFE: While facing recent declines, it managed to show signs of recovery during the same week, indicating potential resilience.

Volume Analysis:

The average volume growth across the group for various timeframes (weekly, monthly, quarterly) demonstrates considerable investor interest and trading activity in these stocks, signifying increased market participation.

Individual Stock Trends:

  1. NVAX: Currently in a downward trend, with historical data suggesting a potential further decline in the near future. Recent trends indicate fluctuating movements between downtrends and uptrends.
  2. PFE: Also in a downward trend, although showing intermittent signs of uptrend amidst the overall decline. Support line analysis suggests cautious monitoring.
  3. MRK: Displays an upward trend, having surpassed its 50-day Moving Average, signifying a shift from a bearish to a bullish trend. Resistance levels indicate potential future movement within a specified range.

Summary:

The performance of Covid-19 vaccine companies has been dynamic, marked by fluctuations in valuation, varied price movements, and changing trends. While some stocks exhibit bullish tendencies, others face challenges in sustaining upward momentum.


Contributor

Dem Sem's AvatarDem Sem|Expert

Interact to see
Advertisement
FICO fell over 9% today, extending a multi‑week downtrend that has already knocked the stock more than 7% lower since its last earnings update. The decline comes despite strong recent financial results, including double‑digit revenue growth, expanding margins, and repeated earnings beats.
RERE fell roughly 10% today, giving back a portion of its strong gains over the past year and month, as traders reacted to fresh earnings and guidance. The company delivered robust Q4 2025 results, with revenue growth near 30% year over year and earnings per share ahead of consensus estimates, underscoring continued operational momentum.
Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5. New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.
Penny stocks in the oil sector are exploding in trading volume amid a massive oil price rally, with the USO ETF hitting a record $12.4 billion in daily trades—up 1,000% YTD and surpassing peaks from 2020, 2022, and 2025. Geopolitical tensions from the ongoing Iran war are driving oil above $100 per barrel, creating supply shocks and opportunities for high-volatility plays in exploration, drilling, and production.
NTSK shares are trading down approximately 20% in premarket trading on March 12, 2026, following the company's Q4 fiscal 2026 earnings release after the close on March 11. The primary catalyst is not the earnings themselves — which beat expectations — but an imminent and massive lock-up expiration scheduled for March 13, 2026, when approximately 390 million shares of Class A common stock become eligible for public sale.
PATH shares fell approximately 10% in premarket trading on March 12, 2026, reversing the prior session's 6.82% gain, as investors digested Q4 fiscal 2026 earnings released after the close on March 11. The primary catalyst for the selloff was disappointing FY2027 revenue guidance, which implies approximately 8–9% top-line growth — a notable deceleration from the 13% growth delivered in FY2026.
TIC shares are down approximately 15% in premarket trading on March 12, 2026, ahead of the regular session open. Primary catalyst: TIC Solutions reported Q4 2025 earnings before market open, posting an adjusted loss of $0.25 per share — a miss of $0.33 against the analyst consensus of -$0.08 per share.
HIMX shares surged approximately +33% in premarket trading on March 12, 2026, with the stock climbing from a prior close of $9.15 to around $12.19–$12.56. The primary catalyst is a renewed wave of AI-driven semiconductor enthusiasm surrounding Himax's Co-Packaged Optics (CPO) technology and its potential role as a supplier to major players including NVIDIA and Taiwan Semiconductor Manufacturing.
GIII shares fell approximately 15.65% in early trading on March 12, 2026, after the company reported its fiscal Q4 and full-year 2026 earnings before the bell. Q4 net sales dropped 8.1% year-over-year to $771.5 million, missing Wall Street's consensus estimate of approximately $792 million.
LWLG shares surged approximately 42% in early trading on March 12, 2026, building on a 15% rally from the prior session, as the stock's multi-day momentum accelerated into the regular open. The primary catalyst is Lightwave Logic's newly announced silicon photonics development agreement with Tower Semiconductor (TSEM), integrating its electro-optic polymer modulator technology into Tower's PH18 platform.
IperionX (NASDAQ: IPX) shares fell approximately 15% in Thursday's session, with the ADR trading around $42.70 after closing at $50.26 the prior session. The primary catalyst was the company's half-year financial report (H1 FY2026, ending December 31, 2025), which revealed a sharply wider net loss of US$34.8 million — more than double the US$16.2 million loss reported in the prior corresponding period.
SITM shares are down approximately 10% in Thursday's trading session, extending a multi-week decline from February highs near $447. The primary catalyst is a broad-based semiconductor sector selloff driven by intensifying tariff fears and macro uncertainty under the Trump administration's escalating trade policy.
RHLD shares dropped over 24% today, accelerating a recent downtrend that had already left the stock roughly 15–17% lower over the past month before today’s earnings‑driven selloff. For 2025, Resolute reported sales of about $462 million, up modestly from the prior year, but its net loss widened to roughly $5.9 million versus a $2.3 million loss in 2024.
VEON shares fell more than 14% today, a sharp reversal that follows a 12‑month gain of roughly 120% and year‑to‑date return near 45%, leaving the stock vulnerable to profit‑taking.​ The move comes just one day before VEON is scheduled to release its Q4 and full‑year 2025 results, prompting pre‑earnings de‑risking from traders who had enjoyed substantial gains.​
Applied Optoelectronics (AAOI) Stock Falls Over -14% as Overheated Rally Meets Profit-Taking and Valuation Jitters
AERO fell over 14% today, trading as low as about $14.15 and recently changing hands near $14.41, down from a prior close around $16.80 and marking a new 12‑month low. The drop follows a brief rally earlier this week, but the stock remains down more than 20% over the past year despite Grupo Aeromexico posting record 2025 margins and robust profitability. Investors appear concerned that management’s bullish 2026 guidance — calling for mid‑ to high‑single‑digit revenue growth and high‑20% EBITDA margins — may prove challenging amid cost inflation and competitive pressures.
EVCM shares are plunging approximately 23% in premarket trading on March 13, 2026, following the company's Q4 2025 earnings release after the prior session's close. The primary catalyst is a significant EPS miss — EverCommerce reported adjusted EPS of $0.03, badly missing the consensus estimate of $0.05, a 40% negative earnings surprise.
ADBE shares are down approximately 8.67% in premarket trading on March 13, 2026, erasing gains from the prior session. The primary catalyst is the surprise announcement that longtime CEO Shantanu Narayen will step down after 18 years once a successor is named.
ULTA shares are declining sharply in premarket trading on March 13, 2026, extending losses that began after the company's earnings release after the close on March 12 — with the stock down approximately 8.3% in premarket, building on a -4.28% decline during the regular session on March 12. The primary catalyst is fiscal 2026 earnings guidance that fell short of Wall Street expectations, with the company projecting diluted EPS of $28.05–$28.55 against analyst consensus of approximately $28.58.
EONR is trading approximately +10% higher in Friday's premarket session, extending a powerful multi-day rally that has seen the stock surge over 250% year-to-date. The primary catalyst is the company's newly expanded oil hedging program, locking in favorable pricing through 2027 as oil prices spike amid geopolitical tensions in the Middle East.
Vaccine Stocks Surge: $NVAX, $MRK, $PFE, $JNJ, $MRNA Up in a Week